A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen
/in Breast Cancer, Colorectal Cancer, Dendritic Cells, International Publications, Ovarian Cancer, Pancreatic CancerCellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells
/in Dendritic Cells, Hypernephroma, International PublicationsMature dendritic cells induce T-helper type-1-dominant immune responses in patients with metastatic renal cell carcinoma
/in Dendritic Cells, Hypernephroma, International PublicationsPulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice
/in Dendritic Cells, International Publications, Soft Tissue SarcomaInduction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
/in Colorectal Cancer, Dendritic Cells, International PublicationsFollow-up evaluation of prostate cancer patients infused with autologous dendritic cells pulsed with PSMA peptides
/in Dendritic Cells, International Publications, Prostate CancerRegression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
/in Dendritic Cells, International Publications, Urothelial CarcinomaPhase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen
/in Dendritic Cells, International Publications, Prostate CancerDistribution of S-100 protein-positive dendritic cells and expression of HLA-DR antigen in transitional cell carcinoma of the urinary bladder in relation to tumour progression and prognosis
/in Dendritic Cells, International Publications, Urothelial Carcinoma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer